{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:58:54Z","timestamp":1791773934323,"version":"4.3.4"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T00:00:00Z","timestamp":1656028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s10620-022-07598-2","type":"journal-article","created":{"date-parts":[[2022,6,24]],"date-time":"2022-06-24T13:02:37Z","timestamp":1656075757000},"page":"451-459","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["CD8+\u2009Lymphocyte Infiltration Is a Specific Feature of Colitis Induced by Immune Checkpoint Inhibitors"],"prefix":"10.1007","volume":"68","author":[{"given":"Yoshiyuki","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0091-8343","authenticated-orcid":false,"given":"Tadanobu","family":"Nagaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugo","family":"Iwaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Okamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Hirayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Iwaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Uehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeji","family":"Umemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,24]]},"reference":[{"issue":"7378","key":"7598_CR1","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480\u2013489.","journal-title":"Nature."},{"issue":"4","key":"7598_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u2013264.","journal-title":"Nat Rev Cancer."},{"issue":"4","key":"7598_CR3","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"SL Topalian","year":"2015","unstructured":"Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450\u2013461.","journal-title":"Cancer Cell."},{"issue":"9","key":"7598_CR4","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1093\/annonc\/mdv182","volume":"26","author":"TW Chen","year":"2015","unstructured":"Chen TW, Razak AR, Bedard PL et\u00a0al. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015;26:1824\u20131829.","journal-title":"Ann Oncol."},{"issue":"8","key":"7598_CR5","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nrclinonc.2016.58","volume":"13","author":"C Boutros","year":"2016","unstructured":"Boutros C, Tarhini A, Routier E et\u00a0al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016;13:473\u2013486.","journal-title":"Nat Rev Clin Oncol."},{"issue":"4","key":"7598_CR6","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","volume":"27","author":"S Champiat","year":"2016","unstructured":"Champiat S, Lambotte O, Barreau E et\u00a0al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559\u2013574.","journal-title":"Ann Oncol."},{"issue":"1","key":"7598_CR7","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1186\/s12885-019-6150-y","volume":"19","author":"K Masuda","year":"2019","unstructured":"Masuda K, Shoji H, Nagashima K et\u00a0al. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. BMC Cancer. 2019;19:974.","journal-title":"BMC Cancer."},{"issue":"4","key":"7598_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","volume":"16","author":"JS Weber","year":"2015","unstructured":"Weber JS, D\u2019Angelo SP, Minor D et\u00a0al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16:375\u2013384.","journal-title":"Lancet Oncol."},{"issue":"12","key":"7598_CR9","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2017.08.022","volume":"12","author":"S Teraoka","year":"2017","unstructured":"Teraoka S, Fujimoto D, Morimoto T et\u00a0al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12:1798\u20131805.","journal-title":"J Thorac Oncol."},{"issue":"4","key":"7598_CR10","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et\u00a0al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320\u2013330.","journal-title":"N Engl J Med."},{"issue":"7","key":"7598_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD et\u00a0al. Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35:785\u2013792.","journal-title":"J Clin Oncol."},{"issue":"8","key":"7598_CR12","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O\u2019Day SJ, McDermott DF et\u00a0al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711\u2013723.","journal-title":"N Engl J Med."},{"key":"7598_CR13","first-page":"11","volume":"10","author":"D Berman","year":"2010","unstructured":"Berman D, Parker SM, Siegel J et\u00a0al. Blockade of cytotoxic T-lymphocyte antigen-4 by ipilimumab results in dysregulation of gastrointestinal immunity in patients with advanced melanoma. Cancer Immun. 2010;10:11.","journal-title":"Cancer Immun."},{"issue":"9","key":"7598_CR14","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1097\/MCG.0b013e31828f1d51","volume":"47","author":"KA Mitchell","year":"2013","unstructured":"Mitchell KA, Kluger H, Sznol M et\u00a0al. Ipilimumab-induced perforating colitis. J Clin Gastroenterol. 2013;47:781\u2013785.","journal-title":"J Clin Gastroenterol."},{"issue":"6","key":"7598_CR15","doi-asserted-by":"publisher","first-page":"805","DOI":"10.3109\/0284186X.2012.682630","volume":"51","author":"M Slingerland","year":"2012","unstructured":"Slingerland M, Nortier JW, Veenendaal RA et\u00a0al. Severe colitis while responding to ipilimumab in metastatic melanoma. Acta Oncol. 2012;51:805\u2013807.","journal-title":"Acta Oncol."},{"issue":"15","key":"7598_CR16","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","volume":"24","author":"KE Beck","year":"2006","unstructured":"Beck KE, Blansfield JA, Tran KQ et\u00a0al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006;24:2283\u20132289.","journal-title":"J Clin Oncol."},{"issue":"13","key":"7598_CR17","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"ME Valsecchi","year":"2015","unstructured":"Valsecchi ME. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270.","journal-title":"N Engl J Med."},{"issue":"4","key":"7598_CR18","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/j.cgh.2016.09.017","volume":"15","author":"S Yanai","year":"2017","unstructured":"Yanai S, Nakamura S, Matsumoto T. Nivolumab-induced colitis treated by infliximab. Clin Gastroenterol Hepatol. 2017;15:e80\u2013e81.","journal-title":"Clin Gastroenterol Hepatol."},{"key":"7598_CR19","doi-asserted-by":"publisher","first-page":"360","DOI":"10.12659\/AJCR.908570","volume":"19","author":"T Iyoda","year":"2018","unstructured":"Iyoda T, Kurita N, Takada A et\u00a0al. Resolution of infliximab-refractory nivolumab-induced acute severe enterocolitis after cyclosporine treatment in a patient with non-small cell lung cancer. Am J Case Rep. 2018;19:360\u2013364.","journal-title":"Am J Case Rep."},{"issue":"6","key":"7598_CR20","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.it.2019.04.002","volume":"40","author":"KE Pauken","year":"2019","unstructured":"Pauken KE, Dougan M, Rose NR et\u00a0al. Adverse events following cancer immunotherapy: obstacles and opportunities. Trends Immunol. 2019;40:511\u2013523.","journal-title":"Trends Immunol."},{"issue":"6","key":"7598_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1053\/j.semdp.2019.07.009","volume":"36","author":"Y Zen","year":"2019","unstructured":"Zen Y, Yeh MM. Checkpoint inhibitor-induced liver injury: a novel form of liver disease emerging in the era of cancer immunotherapy. Semin Diagn Pathol. 2019;36:434\u2013440.","journal-title":"Semin Diagn Pathol."},{"key":"7598_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3389\/fcvm.2019.00003","volume":"6","author":"K Tajiri","year":"2019","unstructured":"Tajiri K, Ieda M. Cardiac complications in immune checkpoint inhibition therapy. Front Cardiovasc Med. 2019;6:3.","journal-title":"Front Cardiovasc Med."},{"key":"7598_CR23","first-page":"168","volume":"26","author":"R Ueno","year":"2019","unstructured":"Ueno R, Nemoto M, Uegami W et\u00a0al. Pembrolizumab-induced pneumonitis with a perilymphatic nodular pattern in a lung cancer patient: a radio-pathologic correlation. Respir Med Case Rep. 2019;26:168\u2013170.","journal-title":"Respir Med Case Rep."},{"issue":"4\u20135","key":"7598_CR24","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.autrev.2014.01.028","volume":"13","author":"K Conrad","year":"2014","unstructured":"Conrad K, Roggenbuck D, Laass MW. Diagnosis and classification of ulcerative colitis. Autoimmun Rev. 2014;13:463\u2013466.","journal-title":"Autoimmun Rev."},{"issue":"11","key":"7598_CR25","first-page":"661","volume":"98","author":"B Veauthier","year":"2018","unstructured":"Veauthier B, Hornecker JR. Crohn\u2019s disease: diagnosis and management. Am Fam Physician. 2018;98:661\u2013669.","journal-title":"Am Fam Physician."},{"issue":"48","key":"7598_CR26","doi-asserted-by":"publisher","first-page":"7302","DOI":"10.3748\/wjg.14.7302","volume":"14","author":"A Theodoropoulou","year":"2008","unstructured":"Theodoropoulou A, Koutroubakis IE. Ischemic colitis: clinical practice in diagnosis and treatment. World J Gastroenterol. 2008;14:7302\u20137308.","journal-title":"World J Gastroenterol."},{"issue":"1","key":"7598_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden WJ. Index for rating diagnostic tests. Cancer. 1950;3:32\u201335.","journal-title":"Cancer."},{"issue":"3","key":"7598_CR28","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1093\/ecco-jcc\/jjv210","volume":"10","author":"K Ikeya","year":"2015","unstructured":"Ikeya K, Hanai H, Sugimoto K et\u00a0al. The ulcerative colitis endoscopic index of severity more accurately reflects clinical outcomes and long-term prognosis than the Mayo endoscopic score. J Crohns Colitis. 2015;10:286\u2013295.","journal-title":"J Crohns Colitis."},{"issue":"6","key":"7598_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/joim.12744","volume":"283","author":"BL Adler","year":"2018","unstructured":"Adler BL, Pezhouh MK, Kim A et\u00a0al. Histopathological and immunophenotypic features of ipilimumab-associated colitis compared to ulcerative colitis. J Intern Med. 2018;283:568\u2013577.","journal-title":"J Intern Med."},{"issue":"5","key":"7598_CR30","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s00262-018-2134-z","volume":"67","author":"KC K\u00e4hler","year":"2018","unstructured":"K\u00e4hler KC, Eigentler TK, Gesierich A et\u00a0al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother. 2018;67:825\u2013834.","journal-title":"Cancer Immunol Immunother."},{"issue":"6","key":"7598_CR31","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s41379-018-0013-y","volume":"31","author":"Y Zen","year":"2018","unstructured":"Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965\u2013973.","journal-title":"Mod Pathol."},{"issue":"8","key":"7598_CR32","doi-asserted-by":"publisher","first-page":"1130","DOI":"10.1097\/PAS.0b013e31817150e3","volume":"32","author":"DA Oble","year":"2008","unstructured":"Oble DA, Mino-Kenudson M, Goldsmith J et\u00a0al. Alpha-CTLA-4 mAb-associated panenteritis: a histologic and immunohistochemical analysis. Am J Surg Pathol. 2008;32:1130\u20131137.","journal-title":"Am J Surg Pathol."},{"issue":"9","key":"7598_CR33","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1111\/cup.13454","volume":"46","author":"JL Curry","year":"2019","unstructured":"Curry JL, Reuben A, Szczepaniak-Sloane R et\u00a0al. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14(+) and CD16(+) monocytes driving an innate immune response. J Cutan Pathol. 2019;46:627\u2013636.","journal-title":"J Cutan Pathol."}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-022-07598-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-022-07598-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T07:50:58Z","timestamp":1675842658000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-022-07598-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":33,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["7598"],"URL":"https:\/\/doi.org\/10.1007\/s10620-022-07598-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"assertion":[{"value":"7 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Shinshu University Hospital Ethics Board.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained for all participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}